CPNP member and Past President Sheila Botts, PharmD, BCPP, has been selected as one of 17 new investigator award recipients at the 2009 New Clinical Drug Evaluation Unit (NCDEU) meeting to be held June 29-July 2 in Hollywood Florida. The NCDEU meeting, sponsored by the National Institute of Mental Health and American Society of Clinical Psychopharmacology, offers a special program for new investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program.
Dr. Botts submitted an abstract describing her current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers’ assessment of the relative value of the specialized program to each applicant at this time in his/her career. Dr. Botts will participate in this special educational workshop and present her poster during the scheduled poster sessions. In addition, they will receive a travel expense award and a certificate acknowledging her participation in the program, presented by the Acting Deputy Director of NIMH, at an award ceremony on Monday evening, June 29.
Dr. Botts’ research project is entitled “Continuity of Antipsychotic Therapy and Effect on Early Relapse.” Abstracts are available online after the conclusion of the 2009 meeting (http://www.ncdeumeeting.org/index.htm). A history of pharmacist award recipients of this award is available at the conclusion of this release. Congratulations to Dr. Botts!
About CPNP
The College of Psychiatric and Neurologic Pharmacist’s (CPNP) mission is to promote excellence in pharmacy practice, education and research to optimize the treatment outcomes of individuals affected by psychiatric and neurologic disorders by:
- Facilitating the dissemination of information regarding psychiatric and neurologic pharmacotherapy, patient care and community support
- Facilitating programs in the areas of psychiatric and neurologic pharmacy at national meetings with organizations which support similar interests
- Improving care for patients with psychiatric and neurologic disorders
- Advancing the quality of research in the pharmacotherapy of psychiatric and neurologic disorders
- Supporting the Psychiatric Pharmacy Certification Exam process and programs preparing exam candidates.
Pharmacist New Investigator Award Recipient History
Data only tabulated since 1992. Not all programs/abstract booklets had degrees listed, tally may under-represent our activity.
2009
| Recipient | Title of Poster Presentation |
Affiliation |
Sheila R. Botts, Pharm.D. |
Continuity of Antipsychotic Medication and Effect on Early Relapse Co-authors: Gao Liu, Joseph Conigliaro, M.D., M.S.P.H.; Jeff Talbert, Ph.D. |
University of Kentucky, Lexington |
2008
| Recipient | Title of Poster Presentation |
Affiliation |
Susan Lakey, Pharm.D. |
Improving Medication Management Support for Older Adults Co-authors: Shelly Gray, Pharm.D.; Soo Borson, M.D. |
University of Washington Department of Psychiatry and Behavioral Sciences, Seattle |
2007
| Recipient | Title of Poster Presentation |
Affiliation |
Douglas Boggs, Pharm.D., M.S. |
The Effect of Venlafaxine on Serium Brain-Derived Neurotrophic Factor (BDNF) in Depressed and Non-Depressed Schizophrenia Patients Co-authors: James Koenig, Ph.D.; Deanna L. Kelly, Pharm.D.; William T. Carpenter, M.D.; Robert R. Conley, M.D. |
Maryland Psychiatric Research Center, Baltimore MD |
Aaron Gibson, Pharm.D. |
A Comparison of Mental Illness and Treatment Type Prevalence Between Foster and Non-Foster Children in the Texas Medicaid System Co-authors: M. Lynn Crismon, Pharm.D.; Michael T. Johnsrud. Ph.D.; Kenneth A. Lawson, Ph.D.; Rick Allgeyer, Ph.D. |
The University of New Mexico |
2006
| Recipient | Title of Poster Presentation |
Affiliation |
Megan Ehret, Pharm.D. |
Determining the Mechanism of a Drug-Drug Interaction: Venlafaxine and P-Glycoprotein Co-authors: Gary M. Levin, Pharm.D., Madhusudhanan Narasimhan, Ph.D., Appu Rathinavelu, Ph.D. |
Nova Southeastern University |
2005
| Recipient | Title of Poster Presentation |
Affiliation |
Anthony DeLeon, Pharm.D. |
Antipsychotic Polypharmacy: Pharmacoepidemiology and Potential Predictors of Utilization Co-authors: M. Lynn Crismon, Alexander Miller, Kenneth Lawson, Tawny Bettinger |
UT-Austin |
2004
| Recipient | Title of Poster Presentation |
Affiliation |
Nick Patel, Pharm.D. |
Adherence To Clozapine: Effects of Reduced Frequency of Hematologic Monitoring Co-authors: M. Lynn Crismon, Michael Johnsrud, Alexander Miller |
UT-Austin |
2003 – None
2002
| Recipient | Title of Poster Presentation |
Affiliation |
Jennifer Baumgartner, Pharm.D. |
Evaluation of a Patient and Family Education Program for Children and Adolescents with ADHD |
Children's Medical Center, Dallas, TX and UT-Austin |
Tawny Bettinger, Pharm.D. |
Clinician Adherence to a Major Depressive Disorder Algorithm in the Texas Public Mental Health Sector |
UT-Austin and UT- |
2001
| Recipient | Title of Poster Presentation |
Affiliation |
Robert Bies, Pharm.D. |
Capturing Drug Exposures In Large Effectiveness Trials |
University of Pittsburgh |
Christian Teter, Pharm.D. |
Effects of Nicotine and Tobacco Smoking on the Topographic EEG |
University of Michigan |
Jessica Wehner, Pharm.D. |
Gabapentin Associated Mania: A Retrospective, Naturalistic Review |
Northwest Missouri Psychiatric Rehabilitation Center |
2000
| Recipient | Title of Poster Presentation |
Affiliation |
William Clark, Pharm.D. |
One Year Review of Outcomes of Atypical Antipsychotics Use at a VA Health Care System |
Central Texas Veterans Health Care System |
Lizbhet Delgado, Pharm.D. |
A Comparison of Clinical Outcomes in Patients Receiving Depot vs. Atypical Antipsychotics |
Nova Southeastern Univ. |
1999
| Recipient | Title of Poster Presentation |
Affiliation |
Louise Cohen, Pharm.D. |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder (ADHD) in Psychiatrically Referred Girls |
Massachusetts General Hospital |
Lack of Pharmacokinetic Interaction Between Desipramine and a2 Adrenergic Agonists in Children and Adolescents |
Massachusetts General Hospital |
|
Jodi Worrel, Pharm.D. |
Hypertriglyceridemia and Endocrine Complications Associated with Propranolol Use in Psychiatric Patients |
Univ. of Missouri – Kansas City School of Pharmacy |
1998
| Recipient | Title of Poster Presentation |
Affiliation |
Roger Drake, Pharm.D. |
Baclofen Treatment for Chronic PTSD: An Open Trial |
VA Medical Center, Tuscaloosa & Samford University |
Deanna Kelly, Pharm.D. |
Sex Differences in Olanzapine Response in Treatment-Resistant Schizophrenia |
University of Maryland |
1997
| Recipient | Title of Poster Presentation |
Affiliation |
Steven Stoner, Pharm.D. |
Antidepressant Overdoses and Resultant Emergency Department Services: The Impact of SSRIs |
University of Missouri-Kansas City School of Pharmacy |
1996
| Recipient | Title of Poster Presentation |
Affiliation |
Cara Alfaro (Riesenman), Pharm.D. |
In Vivo Relationshiop of SSRI Plasma Concentration with CYP2D6 Inhibition |
Univ. of TX Health Science Center at San Antonio |
Mark Bunker, Pharm.D. |
Longitudinal Analysis of Abnormal Involuntary Movements in Long-Term Clozapine-Treated Patients |
University of Missouri-Kansas City School of Pharmacy |
Gary Levin, Pharm.D. |
A Comparison of Patient-Related Burden, Side Effect Incidence, and Compliance: Lithium Versus Valproate |
Union University, Albany |
1995
| Recipient | Title of Poster Presentation |
Affiliation |
Andrea Eggert, Pharm.D. |
Evaluation of Potential Nonlinear Lithium Clearance |
University of Texas at Austin & Austin State Hospital |
Gary Ellenor, Pharm.D. |
The Comparative Efficacy of Divalproex Low- and High-Serum Level in Bipolar Disorder and Schizophrenia |
Veterans Affairs Medical Center, San Diego |
Daniel Still, Pharm.D. |
Effects of Risperidone in Clozapine-Treated Schizophrenic Patients |
University of Texas at Austin & Austin State Hospital |
1994
| Recipient | Title of Poster Presentation |
Affiliation |
Eugene Makela, Pharm.D. |
Obsessive-Compulsive Syptoms and Standardized Reading Test Scores |
West Virginia University |
José Rey, Pharm.D. |
Preliminary Report: An Observational Evaluation of Paroxetine in a VA Population |
Southeastern University and Miami Veterans Affairs Medical Center |
1993
| Recipient | Title of Poster Presentation |
Affiliation |
Jonathan Lacro, Pharm.D. |
Subclinical Tremor: A Possible Risk Factor for Tardive Dyskinesia |
Veterans Affairs San Diego Healthcare System |
Robert Littrell, Pharm.D. |
Characterization and Sequelae of Overt Noncompliance with Psychotropic Agents |
University of Kentucky |
1992
| Recipient | Title of Poster Presentation |
Affiliation |
Rob Dufresne, Ph.D. |
Thioridazine Improves Affective Symptoms in Schizophrenic Patients |
University of Rhode Island |
Kim Lusk, Pharm.D. |
Factors Associated With Readmission in First-Admission Schizophrenia |
University of Tennessee |